Shire PLC (LON:SHP) had its price objective boosted by Berenberg Bank from GBX 5,900 ($77.60) to GBX 6,000 ($78.92) in a research note released on Monday, November 6th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other research firms have also commented on SHP. J P Morgan Chase & Co reaffirmed an overweight rating and set a GBX 5,300 ($69.71) target price on shares of Shire in a report on Monday, October 30th. Liberum Capital dropped their price objective on Shire from GBX 4,400 ($57.87) to GBX 4,200 ($55.24) and set a hold rating on the stock in a report on Tuesday, October 24th. Deutsche Bank AG reduced their price objective on Shire from GBX 6,000 ($78.92) to GBX 5,700 ($74.97) and set a buy rating on the stock in a research report on Tuesday, September 5th. Barclays PLC restated an equal weight rating and issued a GBX 4,000 ($52.61) target price on shares of Shire in a research report on Monday, October 30th. Finally, Credit Suisse Group reissued an outperform rating and set a GBX 5,350 ($70.37) target price on shares of Shire in a research note on Tuesday, August 22nd. Four analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Shire has an average rating of Buy and a consensus target price of GBX 5,250 ($69.05).
Shares of Shire (LON:SHP) traded down GBX 24 ($0.32) during midday trading on Monday, hitting GBX 3,711 ($48.81). The company had a trading volume of 1,797,580 shares, compared to its average volume of 2,890,000. Shire has a 1 year low of GBX 3,435.50 ($45.19) and a 1 year high of GBX 5,067 ($66.64).
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with our FREE daily email newsletter.